These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22288066)

  • 1. Large-cell neuroendocrine cancer of the colon following rituximab-based lymphoma treatment.
    Freeman HJ; Kwan PW; Webber D
    Can J Gastroenterol; 2012 Jan; 26(1):12-3. PubMed ID: 22288066
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
    Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
    Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
    J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
    Coiffier B; Salles G
    Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
    Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
    Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary.
    Ahbeddou N; Fetohi M; Khanoussi BE; Errihani H
    Arch Gynecol Obstet; 2011 May; 283(5):1173-4. PubMed ID: 20957380
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 10. Diffuse large B-cell lymphoma with germinal center B-cell phenotype mimicking primary effusion lymphoma.
    Lim Y; Kim TY; Choi IS; Kim BS; Lee TS; Kim JE; Chang MS; Kim KH
    J Clin Oncol; 2011 Apr; 29(10):e271-3. PubMed ID: 21220599
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
    Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
    J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of inadequate doses of rituximab in the treatment of diffuse large B cell lymphoma in Malaysian patients.
    Gan GG; Subramaniam R; Bee PC; Chin EF; Abdul-Halim H; Tai MC
    Asian Pac J Cancer Prev; 2014; 15(4):1703-6. PubMed ID: 24641394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
    Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
    Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
    [No Abstract]   [Full Text] [Related]  

  • 14. Testicular lymphoma.
    Thomas LC; Adonizio C; Filicko-O'Hara J; Golshayan AR; Costa LJ; Morris GJ
    Semin Oncol; 2010 Dec; 37(6):549-54. PubMed ID: 21167372
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
    Pantelaki I; Tigges C; Nußbaum T; Oellig F; Wieland U; Kreuter A
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508527
    [No Abstract]   [Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.
    Ninomiya S; Hara T; Tsurumi H; Goto N; Saito K; Seishima M; Takami T; Moriwaki H
    Leuk Lymphoma; 2012 Jun; 53(6):1143-5. PubMed ID: 22112045
    [No Abstract]   [Full Text] [Related]  

  • 19. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Lugtenburg P; Avivi I; Berenschot H; Ilhan O; Marolleau JP; Nagler A; Rueda A; Tani M; Turgut M; Osborne S; Smith R; Pfreundschuh M
    Haematologica; 2017 Nov; 102(11):1913-1922. PubMed ID: 28935843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.